Unlocking the Value of Pathology Data with Biobase & TechcyteWatch the recording · 36 min · plays from YouTube

A lab that scans on Techcyte Fusion already holds research-ready assets; connecting Fusion to Biobase makes them searchable, releasable, and licensable, and the lab approves every release. That is the case Todd Parker, CEO and co-founder of Biobase, made in episode 34 of Techcyte’s Pioneers in Digital Pathology series, recorded in October 2026. Jacob Hicks, VP Sales at Techcyte, hosted. Biobase is the data partner in the Techcyte Fusion Partner Program, and Atlas, Biobase’s federated biobanking tool, connects natively to Fusion.

Why do scanned pathology archives sit unused?

A lab on Fusion has already done the hard part: its slides are digital. Most of those images still sit in the archive, for three reasons.

  • No index. A pharma team asks for a few thousand cases matching specific criteria. The answer is buried in PDF reports and LIS fields, so nobody can say quickly what exists.
  • No safe way out. De-identification, consent checks, contracts, and transfer all land on lab staff who already have full days.
  • No buyer on the line. Research teams spend months on RFPs and calls looking for this material, and the requests never reach the lab.

One pathology partner holds about 6 million archived slides and sees about 180,000 cytology cases a year. None of it was searchable by a buyer before it connected.

Who buys pathology data?

Three groups, and all of them want multimodal data.

  • Biopharma, for translational research, biomarker discovery, companion diagnostics, and AI training.
  • Diagnostic and AI developers, for training and validation sets, and specimens to build and validate assays.
  • CROs and research institutions, for feasibility, cohort analytics, and retrospective studies.

A typical request: 500 pancreatic cancer cases with paired whole-slide images, IHC, and molecular data, matched to 5-year outcomes. The value is in the pairing. A lab on Fusion usually has the image and the report; the rest can be linked from its network.

What drives the price of pathology data?

Three things set the price of a case: how rare it is, how well it is paired with molecular and longitudinal data, and how much follow-up comes with it. Normal tissue has value too, because models need a baseline.

A broker takes possession and pays once. A licensed slide can be licensed again to each new buyer, and the lab earns each time.

What stops a lab from licensing its data?

  • Cataloging. Agents read Fusion and LIS data, map it into one model, and extract fields from reports, so every case becomes searchable without manual abstraction. See what a feasibility count is.
  • De-identification. Patient identifiers never leave the site. Labels come off every image and Biobase IDs go on; blocks and glass slides are relabeled the same way.
  • Chain of custody. Every slide, block, image, and file is tracked from the moment it is pulled to delivery, with a full audit trail.
  • Licensing. Standard terms instead of one-off contracts. Biobase manages the BAA and DUA, and the lab earns on every license.

The lab stays in control. Its rules follow its data: if it does not allow genomic use, or certain destinations, its cases drop out of matching queries automatically. It approves or declines every release. Every buyer signs a no-re-identification covenant.

How does the Biobase and Techcyte connection work?

  1. Scan. Slides are digitized and stored in Fusion, as today.
  2. Connect. The lab opts in to the native Biobase connection. No HL7 or FHIR project: it can be on in about a week, against three to nine months for a typical integration.
  3. Prepare. Biobase de-identifies, checks quality, and indexes every case.
  4. Match. Biobase matches incoming requests to the lab’s inventory.
  5. Approve. The lab sees each request, its use case, and its price, and says yes or no.
  6. Deliver. Biobase contracts the buyer, delivers the data, and pays the lab.

The lab makes two decisions: opt in, and approve. The historical archive can join through a one-time LIS export without PHI fields; new cases join through Fusion. The same connection gives access to operational tools: cohort discovery in plain English is live, and specimen tracking, coding suggestions, and trial feasibility are in pilot. The steps are covered in more depth in how a clinical archive becomes a research-ready cohort.

What happens in a lab’s first 30 days?

  • Week 1. Scoping call, compliance review, partnership agreement.
  • Week 2. The lab turns on the connection and sends a sample LIS export; Biobase returns a field mapping.
  • Week 3. Biobase de-identifies, checks, and indexes cases, and matches them to open requests.
  • Week 4. Quotes go out, the lab approves each release, and its dashboard goes live.

From the lab: a data owner or IT contact and a few hours across the month. Biobase handles contracting, compliance, delivery, and payment, and the lab shares in every data or tissue order. To prepare, see preparing a collection for a research partnership.

What does this mean for research teams?

The same mechanics decide what a research team can get. Requests reach labs that were not reachable before, across academic centers, reference labs, community health systems, and pathology groups. Each site approves its own release, and data arrives under standard terms. In one case Todd described, a top-15 pharma company had been looking for a cohort for over a year; it was delivered in two weeks, and the company reordered eight times in the next two months. A precise request is still what makes matching work: see what to include in a biospecimen request.

Questions from the audience

What surprises labs about the value of their archive?

That normal cases are valuable. Rare cancers are the obvious assets, but model training needs a baseline, so tissue without disease is in demand too. Biobase can run a retrospective look at an archive to estimate its value per year.

What should a lab bring to a first call?

The tissue types it sees routinely and their volumes, its current and historical LIS, the systems around Fusion, and its network: hospital access and any EHR connection.

How are restrictions on reuse enforced?

By contract first. Buyers are large, compliance-driven organizations bound by the restrictions in their license. Todd added that Biobase is developing fingerprinting for digital assets, to trace a file that leaves the institution it was licensed to.

How does Biobase get the most value from a slide?

By pricing on supply and demand: how common the case is on one side, and what pharma pipelines and AI developers need on the other. Price does not change by customer. It rises with what stacks on the case: molecular, genomic, longitudinal, and outcomes data.

What happens if a lab leaves?

Its node is switched off and its data is excluded from future sales. Data already licensed stays licensed, unless the buyer breaches the license.